Please assess the completion status of the following clinical trial:

Trial Title: Tranexamic Acid to Reduce Blood Loss in Hemorrhagic Caesarean Delivery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Experimental group: Each patient~* experiencing a bleeding volume of more than 800 mL~* due to surgery or to atony uterine~* during an elective or non-emergent caesarean section~* secondary post-partum haemorrhage after caesarean section, even if CS has been emergent~* after complete information and consent signature.~* covered by social security. Reference non-hemorrhagic group: Each patient~* experiencing a bleeding volume of strictly less than 800 mL~* during an elective or emergent caesarean section~* after complete information and consent signature.~* covered by social security.~Exclusion Criteria:~Patient unable to consent (\<18 years old or incapable people and specially protected mentioned in the article L1121-5 to L1121-8) RCP medical contraindication to tranexamic acid such as~* Hypersensibility to the product or excipient,~* Previous or ongoing arterial or venous thrombosis,~* Coagulopathy, except DIC associated with a predominant fibrinolytic profile,~* Renal failure,~* Previous seizures,~* intrathecal or intraventricular administration. Obstetrical contraindication to TA~* Severe HELLP syndrome (platelet count \<50 000/m3 or renal failure prior to the caesarean (RIFLE score\>2) Protocol related contraindication to inclusion~* Administration of TA before inclusion-Inherited haemorrhagic diseases and low molecular weight heparin within 24 hours before inclusion~* Patients who participated in a study on the efficacy of an experimental drug in the two month preceding the caesarean section~* Inherited haemorrhagic diseases or low molecular weight heparin within 24 hours before inclusion~* Previous inclusion in an interventional trial since the 2 months before CS

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- tranexamic acid 1 g (TA1) (Type: EXPERIMENTAL): To measure the efficacy of a standard 1g dose TA to reduce blood loss in ongoing hemorrhagic cesarean section.~To correlate this clinical effect with the fibrinolysis inhibition and the TA venous and uterine blood concentration
- tranexamic acid 0.5 g (TA1/2) (Type: EXPERIMENTAL): To measure the efficacy of a low 0,5g dose TA to reduce blood loss in ongoing hemorrhagic cesarean section To correlate this clinical effect with the fibrinolysis inhibition and the TA venous and uterine blood concentration
- Saline Solution (TA0) (Type: PLACEBO_COMPARATOR): To measure the evolution of blood loss without TA in ongoing hemorrhagic cesarean section To correlate this clinical evolution with fibrinolysis.
- NH (Type: NO_INTERVENTION): To measure the reference fibrinolytic activity in non-hemorrhagic cesarean section

Based on this trial design, predict the completion outcome and termination type (if applicable).